Cargando…
SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688798/ https://www.ncbi.nlm.nih.gov/pubmed/34950720 http://dx.doi.org/10.3389/fcvm.2021.791311 |
_version_ | 1784618422215114752 |
---|---|
author | Qiu, Mei Wei, Xu-Bin Wei, Wei |
author_facet | Qiu, Mei Wei, Xu-Bin Wei, Wei |
author_sort | Qiu, Mei |
collection | PubMed |
description | Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al.'s network meta-analysis identified the indirect evidence that SGLT2is vs. GLP1RAs reduced hospitalization for heart failure (HHF) but did not reduce CV death and all-cause mortality (ACM) in patients with type 2 diabetes (T2D). We did another meta-analysis incorporating those CV outcome cohort studies directly comparing SGLT2is with GLP1RAs, and identified that SGLT2is vs. GLP1RAs were significantly associated with the lower risks of not only HHF but also CV death and ACM. These findings may suggest that SGLT2is should be considered over GLP1RAs in terms of preventing CV and all-cause death and HHF in T2D patients. |
format | Online Article Text |
id | pubmed-8688798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86887982021-12-22 SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality Qiu, Mei Wei, Xu-Bin Wei, Wei Front Cardiovasc Med Cardiovascular Medicine Lin et al. recently did a network meta-analysis based on cardiovascular (CV) outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and those of glucagon-like peptide-1 receptor agonists (GLP1RAs). Due to the absence of CVOTs directly comparing SGLT2is with GLP1RAs, Lin et al.'s network meta-analysis identified the indirect evidence that SGLT2is vs. GLP1RAs reduced hospitalization for heart failure (HHF) but did not reduce CV death and all-cause mortality (ACM) in patients with type 2 diabetes (T2D). We did another meta-analysis incorporating those CV outcome cohort studies directly comparing SGLT2is with GLP1RAs, and identified that SGLT2is vs. GLP1RAs were significantly associated with the lower risks of not only HHF but also CV death and ACM. These findings may suggest that SGLT2is should be considered over GLP1RAs in terms of preventing CV and all-cause death and HHF in T2D patients. Frontiers Media S.A. 2021-12-07 /pmc/articles/PMC8688798/ /pubmed/34950720 http://dx.doi.org/10.3389/fcvm.2021.791311 Text en Copyright © 2021 Qiu, Wei and Wei. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Qiu, Mei Wei, Xu-Bin Wei, Wei SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title | SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title_full | SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title_fullStr | SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title_full_unstemmed | SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title_short | SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality |
title_sort | sglt2is vs. glp1ras reduce cardiovascular and all-cause mortality |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688798/ https://www.ncbi.nlm.nih.gov/pubmed/34950720 http://dx.doi.org/10.3389/fcvm.2021.791311 |
work_keys_str_mv | AT qiumei sglt2isvsglp1rasreducecardiovascularandallcausemortality AT weixubin sglt2isvsglp1rasreducecardiovascularandallcausemortality AT weiwei sglt2isvsglp1rasreducecardiovascularandallcausemortality |